www.fdanews.com/articles/169117-boehringer-releases-positive-results-from-two-breast-cancer-trials-of-afatinib

Boehringer Releases Positive Results From Two Breast Cancer Trials of Afatinib

December 15, 2014

Germany-based Boehringer Ingelheim has reported positive results from two trials (LUX-Breast 1 and LUX-Breast 3) evaluating afatinib to treat patients with breast cancer.
Pharmaceutical Business Review